Corbus Pharmaceuticals Debt

CRBP Stock  USD 17.82  0.18  1.02%   
Corbus Pharmaceuticals holds a debt-to-equity ratio of 0.608. At this time, Corbus Pharmaceuticals' Net Debt is relatively stable compared to the past year. As of 12/02/2024, Long Term Debt is likely to grow to about 19.3 M, though Net Debt To EBITDA is likely to grow to (0.15). . Corbus Pharmaceuticals' financial risk is the risk to Corbus Pharmaceuticals stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Corbus Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Corbus Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Corbus Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Corbus Pharmaceuticals' stakeholders.
For most companies, including Corbus Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Corbus Pharmaceuticals Holding, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Corbus Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
1.4421
Book Value
12.357
Return On Assets
(0.29)
Return On Equity
(0.51)
Given that Corbus Pharmaceuticals' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Corbus Pharmaceuticals is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Corbus Pharmaceuticals to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Corbus Pharmaceuticals is said to be less leveraged. If creditors hold a majority of Corbus Pharmaceuticals' assets, the Company is said to be highly leveraged.
As of 12/02/2024, Liabilities And Stockholders Equity is likely to grow to about 50.5 M, while Total Current Liabilities is likely to drop slightly above 16.9 M.
  
Check out the analysis of Corbus Pharmaceuticals Fundamentals Over Time.

Corbus Pharmaceuticals Bond Ratings

Corbus Pharmaceuticals Holding financial ratings play a critical role in determining how much Corbus Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Corbus Pharmaceuticals' borrowing costs.
Piotroski F Score
2
FrailView
Beneish M Score
(5.00)
Unlikely ManipulatorView

Corbus Pharmaceuticals Debt to Cash Allocation

Corbus Pharmaceuticals Holding currently holds 20.88 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Corbus Pharmaceuticals has a current ratio of 3.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Corbus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Corbus Pharmaceuticals Common Stock Shares Outstanding Over Time

Corbus Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Corbus Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Corbus Pharmaceuticals Debt Ratio

    
  39.0   
It seems slightly above 61% of Corbus Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Corbus Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Corbus Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Corbus Pharmaceuticals Corporate Bonds Issued

Corbus Short Long Term Debt Total

Short Long Term Debt Total

11.08 Million

At this time, Corbus Pharmaceuticals' Short and Long Term Debt Total is relatively stable compared to the past year.

Understaning Corbus Pharmaceuticals Use of Financial Leverage

Corbus Pharmaceuticals' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Corbus Pharmaceuticals' current equity. If creditors own a majority of Corbus Pharmaceuticals' assets, the company is considered highly leveraged. Understanding the composition and structure of Corbus Pharmaceuticals' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last ReportedProjected for Next Year
Short and Long Term Debt Total20.9 M11.1 M
Net Debt7.2 M7.5 M
Long Term Debt18.4 M19.3 M
Short Term Debt17.6 M18.5 M
Short and Long Term Debt16.2 M17 M
Long Term Debt Total16.2 M14.4 M
Net Debt To EBITDA(0.16)(0.15)
Debt To Equity(2.35)(2.23)
Interest Debt Per Share 4.42  4.64 
Debt To Assets 0.57  0.39 
Long Term Debt To Capitalization 0.38  0.51 
Total Debt To Capitalization 1.74  1.83 
Debt Equity Ratio(2.35)(2.23)
Debt Ratio 0.57  0.39 
Cash Flow To Debt Ratio(2.23)(2.34)
Please read more on our technical analysis page.

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Corbus Stock

  0.74VALN Valneva SE ADRPairCorr

Moving against Corbus Stock

  0.64VERA Vera TherapeuticsPairCorr
  0.59DRUG Bright Minds Biosciences TrendingPairCorr
  0.56VCYT VeracytePairCorr
  0.51SABSW SAB BiotherapeuticsPairCorr
  0.34DMAC DiaMedica Therapeutics TrendingPairCorr
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Corbus Stock Analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.